DK2721045T3 - Compositions, methods of synthesis and use of carbohydrate targeted agents - Google Patents
Compositions, methods of synthesis and use of carbohydrate targeted agents Download PDFInfo
- Publication number
- DK2721045T3 DK2721045T3 DK12803364.4T DK12803364T DK2721045T3 DK 2721045 T3 DK2721045 T3 DK 2721045T3 DK 12803364 T DK12803364 T DK 12803364T DK 2721045 T3 DK2721045 T3 DK 2721045T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- compound
- glucose
- media
- linker
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Claims (8)
1
1. Sammensætning omfattende et D02S-derivat konjugeret til en monosaccharidligand direkte eller gennem en linker og valgfrit chelateret til et metal, hvori D02S-derivatet har den følgende struktur:
hvori Ri', R2' hver uafhængigt er -OH eller -O-alkyl; Rx er et hydrogen, en linker eller en ligand; R3 er en linker og/eller en ligand; og n er et helt tal fra 1 til 10; linkeren er en aminosyre, et peptid, en aminoalkohol, en polyethylylenglycol, en alkyl, en alkenyl, en alkynyl, et azid, en aromatisk forbindelse, en carboxylsyre eller en ester, idet alkyl, alkenyl eller alkynyl valgfrit er substitueret med en alkyl, et halogen, en nitrogruppe, en hydroxylgruppe, en aminogruppe eller en carboxylgruppe; liganden er en GLUTl-targeteringsdel, hvori GLUT1-targeteringsdelen er en l'-aminosukker, en 2'-aminosukker, en l',2'-diaminosukker eller scutellarin.
2. Sammensætning ifølge krav 1 , hvori linkeren omfatter -(CH2)m-X, hvori X er en hydroxyl-, en amino- eller en carboxylgruppe, og m er et helt tal fra 1 til 10, og hvori linkeren valgfrit kan være substitueret med en alkyl, et halogen, en nitrogruppe, en hydroxylgruppe, en aminogruppe eller en carboxylgruppe.
3. Sammensætning ifølge krav 1, hvori D02S-derivatet har den følgende struktur:
4. Sammensætning ifølge krav 1, hvori D02S-derivatet yderligere omfatter et radioaktivt metal.
5. Sammensætning ifølge krav 4, hvori det radioaktive metal er 68Ga eller 177Lu.
6. Fremgangsmåde til syntese af D02S-derivatet ifølge krav 1, hvilken fremgangsmåde omfatter tilknytning af en forbindelse med den følgende struktur til en fast bærer, direkte eller gennem en linker:
hvori Ri' er -OH og R2 er -O-alkyl.
7. Fremgangsmåde ifølge krav 6, yderligere omfattende radioaktiv mærkning af D02S-derivatet med et radioaktivt metal, hvori det radioaktive metal er 68Ga eller 177Lu.
8. Sammensætning ifølge krav 1, hvori D02S-derivatet er valgt blandt de følgende:
eller
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498950P | 2011-06-20 | 2011-06-20 | |
| PCT/US2012/043255 WO2012177701A2 (en) | 2011-06-20 | 2012-06-20 | Compositions, methods of synthesis and use of carbohydrate targeted agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2721045T3 true DK2721045T3 (da) | 2017-07-24 |
Family
ID=47423183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12803364.4T DK2721045T3 (da) | 2011-06-20 | 2012-06-20 | Compositions, methods of synthesis and use of carbohydrate targeted agents |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9550001B2 (da) |
| EP (1) | EP2721045B1 (da) |
| CA (1) | CA2843313C (da) |
| DK (1) | DK2721045T3 (da) |
| PL (1) | PL2721045T3 (da) |
| WO (1) | WO2012177701A2 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2155262A4 (en) * | 2007-03-27 | 2012-12-19 | Radiomedix Inc | COMPOSITIONS FOR TARGETED THERAPIES AND IMAGERY |
| EP2721045B1 (en) | 2011-06-20 | 2017-04-12 | Radiomedix Inc. | Compositions, methods of synthesis and use of carbohydrate targeted agents |
| GB201300707D0 (en) * | 2013-01-15 | 2013-02-27 | Novartis Ag | Compounds and processes |
| US11207429B2 (en) * | 2014-05-09 | 2021-12-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method and compositions for orally administered contrast agents for MR imaging |
| BR112018074716A2 (pt) | 2016-06-02 | 2019-03-12 | Sanofi | conjugados de um agente farmacêutico e porção capaz de ligar-se a uma proteína sensível à glicose |
| GB201610738D0 (en) * | 2016-06-20 | 2016-08-03 | Ge Healthcare As | Chelate compounds |
| EP3568205B1 (en) | 2017-01-12 | 2023-08-16 | Radiomedix Inc. | Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes |
| CN117603148A (zh) | 2017-05-05 | 2024-02-27 | 探针技术开发及商业化中心 | 双官能螯合物的药代动力学增强及其用途 |
| RU2019139434A (ru) | 2017-05-05 | 2021-06-07 | Сентр фор Проуб Девелопмент энд Коммерсиализэйшн | Моноклональные антитела против igf-1r и их применение |
| US10093741B1 (en) | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| KR20200095507A (ko) | 2017-12-01 | 2020-08-10 | 사노피 | 글루코오스 감지 단백질에 결합할 수 있는 모이어티 및 약제의 신규 접합체 |
| RU2730507C1 (ru) * | 2019-08-27 | 2020-08-24 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Соединение для диагностики опухолей, экспрессирующих псма, и композиция на его основе |
| CN114853827B (zh) * | 2022-06-02 | 2023-11-24 | 南京江原安迪科正电子研究发展有限公司 | 一种葡萄糖衍生配体化合物及其制备方法和应用 |
| CN116655715B (zh) * | 2023-07-27 | 2023-10-20 | 北京炫景瑞医药科技有限公司 | 一种GalNAc衍生物、缀合物、组合物以及它们的用途 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141654A (en) | 1977-05-23 | 1979-02-27 | James V. Massey, III | Standard for calibrating and/or verifying instrument accuracy |
| US5648063A (en) | 1981-07-24 | 1997-07-15 | Schering Aktiengesellschaft | Sterile composition comprising a chelate complex for magnetic resonance imaging |
| US5242679A (en) | 1985-01-14 | 1993-09-07 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| US5175343A (en) | 1985-01-14 | 1992-12-29 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| US4988496A (en) | 1988-05-31 | 1991-01-29 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| CN1033030C (zh) | 1988-06-24 | 1996-10-16 | 唐化学原料公司 | 大环双官能螯合剂及其配合物和抗体共轭物的制备方法 |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| US5605672A (en) | 1993-06-09 | 1997-02-25 | The General Hospital Corporation | Blood pool imaging composition and method of its use |
| FR2725382B1 (fr) * | 1994-10-05 | 1997-01-03 | Commissariat Energie Atomique | Polyazacycloalcanes, complexes tri-, tetra- ou pentaazamacrocycliques, procede de fabrication de ces polyazacycloalcanes substitues ou non et greffes sur un support et utilisations des polyazacycloalcanes |
| US6770261B2 (en) | 1995-06-02 | 2004-08-03 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
| US5707605A (en) | 1995-06-02 | 1998-01-13 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
| US6713045B1 (en) | 1995-06-02 | 2004-03-30 | Research Corporation Technologies, Inc. | Targeted magnetic resonance imaging agents for the detection of physiological processes |
| US5980862A (en) | 1995-06-02 | 1999-11-09 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
| US5739313A (en) | 1995-11-13 | 1998-04-14 | Regents Of The University Of Minnesota | Radionuclide labeling of vitamin B12 and coenzymes thereof |
| IT1284046B1 (it) | 1996-06-21 | 1998-05-08 | Bracco Spa | Processo per la preparazione di tetraazamacrocicli |
| US20040170563A1 (en) | 1997-10-27 | 2004-09-02 | Meade Thomas J. | Magnetic resonance imaging agents for the delivery of therapeutic agents |
| CA2309749A1 (en) | 1997-11-17 | 1999-05-27 | Research Corporation Technologies, Inc. | Magnetic resonance imaging agents for the detection of physiological agents |
| US6071490A (en) | 1998-05-07 | 2000-06-06 | Immunomedics, Inc. | Position emission tomography using gallium-68 chelates |
| EP1148878A4 (en) | 1999-01-26 | 2003-04-02 | Fox Chase Cancer Ct | 1,4,8,11-TETRAAZA-CYCLOTETRADECANE DERIVATIVES AS RADIODIAGNOSTICS AND THE USE THEREOF FOR DETERMINING HYPOXIA AND RADIOR RESISTANCE OF TUMORS |
| US6692724B1 (en) | 1999-10-25 | 2004-02-17 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
| US6565828B2 (en) | 2000-04-07 | 2003-05-20 | Bristol-Myers Squibb Company | Macrocyclic chelants for metallopharmaceuticals |
| US6673333B1 (en) | 2000-05-04 | 2004-01-06 | Research Corporation Technologies, Inc. | Functional MRI agents for cancer imaging |
| EP1286704B1 (en) * | 2000-06-02 | 2014-07-23 | Board of Regents, The University of Texas System | ETHYLENEDICYSTEINE (EC)-glucose analog CONJUGATES |
| US6641797B2 (en) * | 2000-08-11 | 2003-11-04 | Schering Aktiengesellschaft | Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use |
| EP1326523A4 (en) | 2000-10-19 | 2005-01-05 | Gen Hospital Corp | VISUALIZATION OF THE ENZYMATIC ACTIVITY |
| JP2004537573A (ja) * | 2001-08-08 | 2004-12-16 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | 心臓灌流およびビトロネクチン受容体を標的とするイメージング剤の同時イメージング |
| WO2003082301A1 (en) | 2002-03-29 | 2003-10-09 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
| US20050232866A1 (en) | 2004-03-26 | 2005-10-20 | Alerion Biomedical Inc. | Biochemically-activated contrast agents for magnetic resonance imaging |
| EP1797106A1 (en) | 2004-09-07 | 2007-06-20 | Triumf, operating as a joint venture by the Governors of the Universities of Alberta, | Synthesis of radiolabeled sugar metal complexes |
| CA2593256A1 (en) | 2005-01-05 | 2006-07-13 | Board Of Regents, The University Of Texas System | Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications |
| US20060275217A1 (en) | 2005-05-06 | 2006-12-07 | Caravan Peter D | Chemical exchange saturation transfer contrast agents |
| WO2006127842A2 (en) | 2005-05-23 | 2006-11-30 | The Regents Of The University Of California | Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease |
| US8097237B2 (en) | 2005-08-23 | 2012-01-17 | Stc.Unm | Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma |
| US8758723B2 (en) | 2006-04-19 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
| US7586102B2 (en) | 2006-08-14 | 2009-09-08 | Board Of Regents The University Of Texas System | Automated system for formulating radiopharmaceuticals |
| US7842280B2 (en) | 2006-09-06 | 2010-11-30 | Case Western Reserve University | Flexibly labeling peptides |
| EP2155262A4 (en) * | 2007-03-27 | 2012-12-19 | Radiomedix Inc | COMPOSITIONS FOR TARGETED THERAPIES AND IMAGERY |
| WO2009054327A1 (ja) | 2007-10-22 | 2009-04-30 | Osaka Foundation For Trade And Industry | Ｍｒｉ用プローブ |
| US20100316566A1 (en) * | 2008-02-27 | 2010-12-16 | Radiomedix Inc. | Radiolabeled hedgehog derivatives for imaging and therapy |
| CA2738786C (en) * | 2008-09-30 | 2017-12-19 | Mallinckrodt Inc. | A version of fdg detectable by single-photon emission computed tomography |
| US10413621B2 (en) | 2009-10-19 | 2019-09-17 | Case Western Reserve University | Composition and methods for imaging cells |
| EP2721045B1 (en) | 2011-06-20 | 2017-04-12 | Radiomedix Inc. | Compositions, methods of synthesis and use of carbohydrate targeted agents |
| EP2968335B1 (en) | 2013-03-15 | 2019-03-27 | Purdue Research Foundation | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
-
2012
- 2012-06-20 EP EP12803364.4A patent/EP2721045B1/en not_active Not-in-force
- 2012-06-20 CA CA2843313A patent/CA2843313C/en active Active
- 2012-06-20 DK DK12803364.4T patent/DK2721045T3/da active
- 2012-06-20 WO PCT/US2012/043255 patent/WO2012177701A2/en active Application Filing
- 2012-06-20 PL PL12803364T patent/PL2721045T3/pl unknown
- 2012-06-20 US US14/128,347 patent/US9550001B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140228551A1 (en) | 2014-08-14 |
| EP2721045A2 (en) | 2014-04-23 |
| CA2843313C (en) | 2018-02-13 |
| US9550001B2 (en) | 2017-01-24 |
| EP2721045B1 (en) | 2017-04-12 |
| EP2721045A4 (en) | 2014-11-12 |
| CA2843313A1 (en) | 2012-12-27 |
| WO2012177701A2 (en) | 2012-12-27 |
| WO2012177701A3 (en) | 2013-05-10 |
| PL2721045T3 (pl) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2721045T3 (da) | Compositions, methods of synthesis and use of carbohydrate targeted agents | |
| EP3613441B1 (en) | Dual-target imaging molecular probe, preparation method therefor, and application thereof | |
| EP3917626B1 (en) | Psma binding dual mode radiotracer and therapeutic | |
| EP0831938B1 (en) | Radiolabeled peptide compositions for site-specific targeting | |
| US10821195B2 (en) | Compositions for therapeutics, targeted PET imaging and methods of their use | |
| CN114984255B (zh) | 一种放射性核素标记的PSMA-αvβ3双靶点偶联体及其应用 | |
| CA3136979A1 (en) | Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer | |
| CN110420337A (zh) | 一种靶向整合素α6的二聚体多肽放射性药物及其制备方法 | |
| CN110339375A (zh) | 一种靶向HER2的rk多肽放射性药物及其制备方法 | |
| Yang et al. | Fluorine-18 labeled galactosyl-neoglycoalbumin for imaging the hepatic asialoglycoprotein receptor | |
| CN109045313A (zh) | 一种靶向her2的d型多肽放射性药物及制备方法 | |
| US11426395B2 (en) | PSMA inhibitor derivatives for labelling with 99mTc via HYNIC, a radiopharmaceutical kit, radiopharmaceutical preparations and their use in prostate cancer diagnostics | |
| CN110305186B (zh) | 前列腺癌PET诊断试剂68Ga-DOTA-ANCP-PSMA及其制备方法和应用 | |
| Varshney et al. | Solid phase synthesis, radiolabeling and biological evaluation of a 99mTc-labeled αVβ3 tripeptide (RGD) conjugated to DOTA as a tumor imaging agent | |
| CN117777296B (zh) | B7h3亲和体及其诊疗核素标记物的制备方法与应用 | |
| CN115368342B (zh) | 成纤维细胞活性蛋白抑制剂、其放射性核素标记物及制备方法和应用 | |
| JP6764460B2 (ja) | ヘキサ乳糖ＮＯＴＡ誘導体、ヘキサ乳糖陽電子肝臓受容体造影剤のＧａ−６８放射能標識法及びヘキサ乳糖陽電子肝受容体造影剤 | |
| Thapa | Fluorine-18 labeling and simultaneous glycosylation of the model peptide demobesin 1 by the novel prosthetic group, keto-[18 F] FDG | |
| CN118164956A (zh) | 一种hsp90特异性放射性探针的制备方法及应用 | |
| CN117586354A (zh) | 靶向gpc3多肽探针及其在制备诊疗放射性药物中的应用 | |
| CN114853827A (zh) | 一种葡萄糖衍生配体化合物及其制备方法和应用 | |
| CN118165073A (zh) | 一种fap抑制剂及其制备方法和应用 | |
| TW201914617A (zh) | 多鏈醣複合物、放射性多鏈醣造影劑及其用途 | |
| LAZNICKOVA et al. | 99mTc-TETRAPEPTIDES: RADIOLABELLING AND BIODISTRIBUTION IN RATS XA9847980 | |
| Mishra et al. | 99m Tc labelled peptide for imaging of peripheral receptors |